RitaNandaMD

Oncology • Chicago, IL

Breast Cancer, Hematologic Oncology

University of Chicago Medicine

Join to view full profile

Dr. Nanda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nanda's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-834-2484

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2001 - 2005
University of ChicagoResidency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Massachusetts Institute of TechnologyB.S., Chemical Engineering, 1993

Certifications & Licensure

IL State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Metastatic Breast Cancer Network Leadership Award 2015
Cancer Clinical Investigator Team Leadership Award NCI, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Amgen Fellowship Award 2004
Foundation Merit Award ASCO, 2003-2004
Best Fellow Award 2002
Calvin Fentress Research Fellowship Award 1997
Summer Research Award NIH, 1995
National Merit Scholar 1989
Join now to see all

Clinical Trials

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer Start of enrollment: 2007 Aug 01
Terminated
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Phase 1
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Start of enrollment: 2014 Jan 30
Active, not recruiting
Phase 2
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Start of enrollment: 2014 Jan 01
Completed
Phase 1
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 1
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Start of enrollment: 2014 Sep 09
Terminated
Phase 2
Endocrine Response in Women With Invasive Lobular Breast Cancer Start of enrollment: 2015 Sep 30
Active, not recruiting
Phase 2
Roles: Contact
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Start of enrollment: 2017 Mar 28
Active, not recruiting
Phase 2
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer Start of enrollment: 2017 Mar 31
Active, not recruiting
Phase 2
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer Start of enrollment: 2018 Feb 12
Active, not recruiting
Phase 2
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer Start of enrollment: 2018 Jun 21
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Start of enrollment: 2017 Sep 02
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Olaparib In Metastatic Breast Cancer Start of enrollment: 2018 Apr 01
Active, not recruiting
Phase 2
Roles: Principal Investigator
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer Start of enrollment: 2019 Sep 16
Suspended
Roles: Contact, Principal Investigator
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) Start of enrollment: 2020 Jul 02
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Start of enrollment: 2020 Jul 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Start of enrollment: 2020 Sep 23
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Start of enrollment: 2019 Sep 06
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2019 Aug 28
Enrolling by invitation
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Emily Ly, Frederick M Howard, Nan Chen, Olwen Hahn, Gini F Fleming
Journal of Oncology Pharmacy Practice. 2024-12-09
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Posi...
Jincong Q Freeman, Sarah P Shubeck, Nan Chen, Sudha R Yarlagadda, Rita Nanda
Annals of Surgical Oncology. 2024-12-01
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.
Margarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, Marie Dreyer, Ken Hatogai
Breast Cancer Research and Treatment. 2024-11-23

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology
Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study
M C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
Immune Checkpoint Inhibition for Triple-Negative Breast Cancer
Saha P and Nanda R, Oncology and Hematology Review, 1/8/2016
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase 1b KEYNOTE-012 Study
Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L, J Clin Oncol, 1/2/2016
TBCRC 019: phase II trial of nab-PAC with/without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple negative breast cancer
Forero-Torres A, Varley KE, Abramson V, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Stroniolo AM, Traina TA, Patil S, Van Poznak C, Nangia JR, Irvin WJ Jr, Hel..., Clin Cancer Res, 1/16/2015
Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial: TBCRC 019
Paoletti C, Li Y, Muniz MC, Kidwell KM, Aung K, Thomas DG, Brown M, Abramson V, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, V..., Clin Cancer Res, 1/16/2015
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, ..., Clin Cancer Res, 1/1/2015
Surgical Patterns of Care in Patients with Invasive Breast Cancer Treated with Neoadjuvant Systemic Therapy and Breast Magnetic Resonance Imaging: Results of a Seconda...
McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF, Ann Surg Oncol, 1/1/2015
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, ..., Breast Cancer Res Treat, 1/8/2014
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment
Maranville JC, Nanda R, Fleming GF, Skor MN, Di Rienzo A, Conzen SD, Pharmacogenet Genomics, 1/3/2014
Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated with Neoadjuvant Systemic Treatment for Operable Breast Cancer (TBCRC 017)
J De Los Santos, Jennifer, A Cantor, K Amos, A Forero, M Golshan, J Horton, C Hudis, N Hylton, K McGuire, F Meric-Bernstam, I Meszoely, R Nanda, S Hwang, Cancer, 1/15/2013
TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy, and without chemotherapy in patients with HER2 overexpressing b...
MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, AC Pavlick, T Wang, SG Hilsenbeck, C Gutierrez, R Schiff, CK Osborne, JC Chang, J Clin Oncol, 1/10/2013
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastaticbreast cancer
Ma CX, Suman VJ, Goetz M, Haluska P, Moynihan T, Nanda R, Olopade O, Pluard T, Guo Z, Chen HX, Erlichman C, Ellis MJ, Fleming GF, Breast Cancer Res Treat, 1/1/2013
The role of tumor-associated macrophages in breast cancer progression
Obeid E, Nanda R, Fu YX, Olopade OI, Int J Oncol, 1/1/2013
Phase II Trial of Temsirolimus in Patients with Metastatic Breast Cancer
Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade O, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ, Breast Cancer Res Treat, 1/1/2012
“Targeting” triple-negative breast cancer: The lessons learned from BRCA1-associated breast cancers
Nanda R, Seminars in Oncology, 1/1/2011
Population Differences in Breast Cancer: Survey in Indigenous African Women Reveal Overrepresentation of Triple Negative Breast Cancer
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Per..., JCO, 1/24/2009
Advances in Breast Cancer: Pathways to Personalized Medicine
Olopade OI, Grushko TA, Nanda R, Huo D, CCR, 1/15/2008
Promoter methylation of Estrogen Receptor, BRCA1 and FANCF in Sporadic Breast Cancers
Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI, Breast Cancer Research Treatment, 1/12/2007
Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions
Nanda R, RRCT, 1/1/2007
A New Breast Tumor Intrinsic Gene List Identifies Novel Characteristics that are Conserved Across Microarray Platforms
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M,..., BMC Genomics, 1/27/2006
A Common Pattern of Promoter Hypermethylation in Lung and Breast Tumors
Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euh..., PLoS Medicine, 1/1/2006
Genetic testing in an Ethnically Diverse Cohort of High Risk Women: A Comparative Analysis of BRCA1 and BRCA2 Mutations in American Families of European and African A...
Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI, JAMA, 1/19/2005
BRCA1 Promoter Methylation in Sporadic Breast Cancer is Associated with Reduced BRCA1 Copy Number and Chromosome 17 Aneusomy
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, Olopade OI, Cancer Research, 1/1/2005
Join now to see all

Books/Book Chapters

Cancer Biology Review: A Case Based Approach
Chapter: Fundamental of DNA Damage and Repair
P Connell and R NandaEditors: W Stadler.Edition 1st,2013
Cancer Medicine
Chapter: Recurring Chromosome Rearrangements in Human Cancer
DA Levitan, R Nanda, JD Rowley, OI OlopadeEditors: J Holland and E Frei.Edition 6th,2003
Pocket Primary Care
Chapter: Chronic Fatigue Syndrome
Nanda REditors: LK Halasyamani and BP Lucas.Edition 1st,2001

Lectures

Advances in Triple-Negative Breast Cancer
Cancun, Mexico - 1/1/2016
Immunotherapy for the Treatment of Triple-Negative Breast Cancer
Royal College of Physicians, London, United Kingdom - 1/1/2016
Immunotherapy in Oncology
Cancun, Mexico - 1/1/2016
Immunotherapy for Breast Cancer—Hype or Hope?
Huntington Beach, CA - 1/1/2015
Neoadjuvant and Adjuvant Therapy and the Treatment of Early Stage Breast Cancer
Omaha, NE - 1/1/2015
Immunotherapy for Breast Cancer
Chicago, IL, 2015; San Francisco, CA, 2015; Naples, Italy, 2015 - 1/1/2015
Neoadjuvant Chemotherapy for Breast Cancer
Chicago, IL - 1/1/2015
Breast Cancer Updates
Chicago, IL - 1/1/2015
Neoadjuvant clinical trials for breast cancer
1/1/2015
“Targeting” triple-negative breast cancer
Dyer, IN, 2015; New Haven, CT, 2015 - 1/1/2015
A Phase Ib Study of Pembrolizumab (MK-3475) in Patients With Advanced Triple-Negative Breast Cancer
San Antonio, TX - 1/1/2014
Neoadjuvant chemotherapy for triple-negative breast cancer
1/1/2014
A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (nab-paclitaxel, Abraxane®) With or Without Mifepristone for Advanced Breast Cancer
1/1/2013
Genetics and Breast Cancer: Risk Assessment and Genetic Testing
Bellevue, WA - 1/1/2013
The alternatively activated macrophage phenotype correlates with aggressive histopathologic features and poor clinical outcome in early stage breast cancer
Buonas, Switzerland - 1/1/2013
A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Abraxane®) With or Without Mifepristone for Advanced Breast Cancer
San Antonio, TX - 1/1/2013
Neoadjuvant chemotherapy in the very young patient
1/1/2013
Case Studies in HER-2 Positive Breast Cancer
1/1/2013
Triple-negative metastatic breast cancer
Chicago, IL - 1/1/2012
Breast Cancer
1/1/2012
Neoadjuvant chemotherapy for HER2 positive breast cancer
1/1/2012
Neoadjuvant Chemotherapy
1/1/2012
Breast Cancer Clinical Updates from the Best of ASCO
1/1/2011
Tumor-associated macrophages and breast cancer
1/1/2010
Breast Cancer Highlights: An Interdisciplinary Perspective
1/1/2010
Join now to see all

Other

Immunotherapy for triple-negative breast cancer
Numerous Outlets
1/1/2016
Interview on the role of clinical trials for breast cancer
WebMD
1/1/2013
Interview on treatment and research for breast cancer
ABC 7 News
1/1/2012
Interview on triple-negative breast cancer
CBS Chicago News
1/1/2011
Interview on HER2 positive metastatic breast cancer
Chicago Sun Times
1/1/2011
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with muta...
Nanda R and Olopade OI, Breast Diseases: A yearbook
1/1/2003
Join now to see all

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

Who Is at Risk for Triple-Negative Breast Cancer?December 27th, 2022
ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
The Search Intensifies for Cancer Treatments with Fewer Side EffectsSeptember 8th, 2021
Join now to see all

Professional Memberships

American Association for Cancer Research - AACR
Member
American Society of Clinical Oncology - ASCO
Member
SITC
Member